Saireito (114) Increases IC50 and Changes T-Cell Phenotype When Used in Combination with Prednisolone Therapy in Human Peripheral Blood Mononuclear Cells

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_center" colspan="3">IC<sub>50</sub> (<i>μ</i>M)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">PSL</td><td class="align_center">PSL + TJ114</td><td class="align_center">PSL + KR114</td></tr><tr><td class="align_left">0.0947</td><td class="align_center">0.191</td><td class="align_center">0.154</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>IC<sub>50</sub> was calculated using GraphPad Prism v8.0.<br/></div></td></tr></table>

<div>IC<sub>50</sub> for the PSL monotherapy and PSL + 114 combination therapy groups.</div>

Evidence-Based Complementary and Alternative Medicine

tab1

Table 1

Table 1: Saireito (114) Increases IC50 and Changes T-Cell Phenotype When Used in Combination with Prednisolone Therapy in Human Peripheral Blood Mononuclear Cells 

Table 1 | Saireito (114) Increases IC50 and Changes T-Cell Phenotype When Used in Combination with Prednisolone Therapy in Human Peripheral Blood Mononuclear Cells 